Camaro1093 Stocks!

[TH_Stockhunter]

CYTK - will be presenting data in December at a Major ALS (Lou Gehrig’s Disease) conference from Dec 11th-13th. This Phase II data will be a significant milestone for the company. They have already conducted two interim analyses from this trial both of which produced encouraging pharmacodynamic trends they the hope will be substantiated and supported in the final data to be presented.
CK-2017357 is currently the subject of a Phase IIa clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis.

Data Ph2a Amyotrophic lateral sclerosis at 21st International Symposium on ALS/MND Dec 11-13

52 wk low is $2.03 and 52 wk high is $3.78.